Answers are grounded in this paper and cite their sources.
To determine long-term efficacy of fremanezumab in patients with episodic or chronic migraine (EM/CM) considered inadequate responders after 3 months of double-blind (DB) treatment.
No takes yet. Share an insight, caveat, or question.
Silberstein et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: